Craig Lipset is a recognized leader at the forefront of innovation in clinical research and medicine development. He is an advisor to technology and biopharmaceutical companies, leading universities, and the venture community, bringing vision and driving action at the intersection of research, digital solutions, and patient engagement. Craig was the Head of Clinical Innovation and Venture Partner at Pfizer, on the founding Operations Committee for TransCelerate Biopharma, and on the founding management teams for two successful startup ventures. During that time, Craig designed and launched multiple industry firsts -- from the first fully-virtual clinical trial for a new medicine to the first returning of results and data to research participants. He serves on the Board of Directors for the Foundation for Sarcoidosis Research, the MedStar Health Research Institute, and the People-Centered Research Foundation (the central office for PCORnet), as well as the Editorial Board for Therapeutic Innovation & Regulatory Science.
Patient Participation And Engagement In Clinical Trials
The role of the patient in clinical trials has seen tremendous change over the last decade, and that change is not complete. From serving as a critical voice during study design and planning to ensuring results and learnings reach the participant, research sponsors are seeking to engage patients throughout trial journey.
Precision medicine has incredible promise for patients. Enormous amounts of money and time are invested in developing technologies and targeted therapies. Genomics, proteomics, phosphorylation assays, RNA expression, organoid growth, and testing, and even delicate mass measurement of liquid cancer cells are explored. This innovation must be focused to maximize the benefit to the most important participants in our healthcare system, the patient. This track is about putting patient needs first, and understanding and accessing the latest (cancer) treatment options.